Transmission dynamics of the M184V drug resistance mutation in primary HIV infection.

OBJECTIVES M184V in HIV-1 reverse transcriptase is among the most common mutations in patients failing antiretroviral therapy but is found only rarely in cases of transmitted drug resistance. METHODS To investigate this apparent paradox, we developed an allele-specific real-time PCR (AS-PCR) assay to determine the transmission of M184V in newly infected individuals. RESULTS M184V transmission may occur to a greater extent than previously thought. Persistence of M184V may commonly involve linkage to other drug resistance mutations. The presence of M184V as a single substitution in newly infected individuals was shown to wane over time, as a likely consequence of reversion and overgrowth by more fit wild-type viruses. CONCLUSIONS The M184V mutation can be documented in newly infected individuals, and the alternative hypothesis that this substitution might impact on the ability of HIV to be transmitted is unfounded.

[1]  K. Metzner,et al.  Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.

[2]  D. Pillay,et al.  Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance * , 2011, HIV medicine.

[3]  M. Wainberg,et al.  Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection , 2009, Antimicrobial Agents and Chemotherapy.

[4]  Michel Roger,et al.  Transmission networks of drug resistance acquired in primary/early stage HIV infection , 2008, AIDS.

[5]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[6]  D. Pillay,et al.  Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003 , 2005, Journal of acquired immune deficiency syndromes.

[7]  K. Metzner,et al.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.

[8]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[9]  M. D. De Pasquale,et al.  Loss of Lamivudine Resistance in a Zidovudine and Lamivudine Dual-Resistant HIV-1 Isolate after Discontinuation of In Vitro Lamivudine Drug Pressure , 1998, Antiviral therapy.

[10]  G. Shaw,et al.  Extensive variation of human immunodeficiency virus type-1 in vivo , 1988, Nature.